amiodarone has been researched along with nifedipine in 58 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 17 (29.31) | 18.7374 |
1990's | 6 (10.34) | 18.2507 |
2000's | 17 (29.31) | 29.6817 |
2010's | 18 (31.03) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Herbette, LG; Mason, RP; Rhodes, DG | 1 |
Belas, F; Chaudhary, AK; Cvetkovic, M; Dempsey, PJ; Fromm, MF; Kim, RB; Leake, B; Roden, DM; Roden, MM; Wandel, C; Wilkinson, GR; Wood, AJ | 1 |
Topliss, JG; Yoshida, F | 1 |
Katoh, M; Nakajima, M; Yamazaki, H; Yokoi, T | 1 |
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
Keserü, GM | 1 |
Nagashima, R; Nishikawa, T; Tobita, M | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Evans, CA; Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Jia, L; Sun, H | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Sen, S; Sinha, N | 1 |
Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Bron, S; Chambon, M; Colau, D; Majjigapu, SR; Michielin, O; Pilotte, L; Röhrig, UF; Turcatti, G; Van den Eynde, BJ; Vogel, P; Zoete, V | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Beaumont, K; Di, L; Maurer, TS; Smith, DA | 1 |
Broustet, JP; Griffo, R; Guern, P; Laylavoix, F; Seriès, E | 1 |
Basiez, M; Labrid, C; Leinot, M; Talvard, J | 1 |
Glossmann, H; Graziadei, I; Moshammer, T; Reider, N; Zech, C; Zernig, G | 1 |
Hollman, A | 1 |
Broustet, JP; Douard, H; Mora, B | 1 |
Ermakova, EN; Gol'dberg, GA; Shakhshneĭder, NM | 1 |
Schwartz, PJ; Vanoli, E | 1 |
Burkart, F; Pfisterer, M | 1 |
Bekhbudova, DA; Bochkareva, EV; Kokurina, EV; Ostrovskaia, TP; Urumbaev, RK | 1 |
Koren, G | 1 |
Bertholet, M; Chevigne, M; Demoulin, JC; Kulbertus, H; Legrand, V; Limet, R; Renier, J; Soumagne, D; Soyeur, D | 1 |
Alvarez Ferreiro, V; Cabades, A; Cebolla Rosell, R; Jordán Iglesias, R; Lorente Cortés, J; Palacios Motilla, V | 1 |
Hess, DS; Scheinman, MM | 1 |
Bertrand, ME; Lablanche, JM; Thieuleux, FA; Tilmant, PY | 1 |
Bertholet, M; Demoulin, JC; Hastir, F; Kulbertus, HE; Renier, J | 1 |
Alegría, E; Arcas, R; Barba, J; Llorens, R; Malpartida, F; Martín Trenor, A | 1 |
Goodwin, JF; McKenna, WJ | 1 |
Araujo, LI; Crosatto, JR; Dyszel, E; Girotti, LA; Kaski, JC; Messuti, H; Rivas, CA; Rosenbaum, MB; Vetulli, HD | 1 |
Astier, H; Grazzini, E; Guipponi, M; Roussel, JP | 1 |
Materukhin, AN; Molodan, AV; Osaulenko, VV; Salgalov, AV | 1 |
Chen, F; Ding, S; Klitzner, TS; Wetzel, GT | 1 |
Sahney, S | 1 |
Cui, WY; Luo, RH; Wang, H; Wang, JA; Wang, SP | 1 |
Kondeva-Burdina, M; Mitcheva, M; Vitcheva, V | 1 |
Bértolo, MB; Coimbra, IB; Costallat, LT; Del Rio, AP; Fernandes, SR; Sachetto, Z | 1 |
Matsumoto, A; Miki, T; Nakaya, H; Nishida, A; Seino, S; Takizawa, T | 1 |
6 review(s) available for amiodarone and nifedipine
Article | Year |
---|---|
Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.
Topics: Cell Membrane; Chemical Phenomena; Chemistry, Physical; Kinetics; Lipid Bilayers; Membrane Lipids; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Structure-Activity Relationship | 1991 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
New antiarrhythmic drugs.
Topics: Amiodarone; Angina Pectoris; Anti-Arrhythmia Agents; Blood Circulation; Bradycardia; Diltiazem; Half-Life; Humans; Hypertension; Lidocaine; Metoprolol; Nadolol; Nifedipine; Propanolamines; Propranolol; Tocainide; Verapamil | 1983 |
[Treatment of coronary arterial spasm].
Topics: Amiodarone; Coronary Vasospasm; Denervation; Diltiazem; Humans; Isosorbide Dinitrate; Myocardial Revascularization; Nifedipine; Nitroglycerin; Phenoxybenzamine; Phentolamine; Reserpine; Verapamil | 1982 |
The natural history of hypertrophic cardiomyopathy.
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Death, Sudden; Humans; Nifedipine; Prognosis; Propranolol; Verapamil | 1981 |
A review of calcium channel antagonists in the treatment of pediatric hypertension.
Topics: Amiodarone; Calcium Channel Blockers; Child; Felodipine; Humans; Hypertension; Isradipine; Nicardipine; Nifedipine; Verapamil | 2006 |
3 trial(s) available for amiodarone and nifedipine
Article | Year |
---|---|
[Effect of the intravenous administration of cordarone on the functional state of the cardiovascular system and the value of the supplementary use of corinfar].
Topics: Amiodarone; Benzofurans; Cardiomyopathy, Dilated; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Hemodynamics; Humans; Injections, Intravenous; Myocardial Contraction; Nifedipine | 1986 |
Effect of short and long term administration of amiodarone on ischaemia-induced left ventricular dysfunction. Implications for combined antianginal drug therapy.
Topics: Adult; Amiodarone; Angina Pectoris; Benzofurans; Coronary Disease; Female; Hemodynamics; Humans; Male; Metoprolol; Middle Aged; Nifedipine; Nitroglycerin | 1985 |
The value of amiodarone for the treatment of unstable angina.
Topics: Adult; Aged; Amiodarone; Angina Pectoris; Angina, Unstable; Benzofurans; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Nifedipine; Random Allocation | 1983 |
49 other study(ies) available for amiodarone and nifedipine
Article | Year |
---|---|
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Male; Mice; Oxidoreductases, N-Demethylating; Pharmacokinetics; Substrate Specificity | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport.
Topics: Amiodarone; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium Channel Blockers; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Daunorubicin; Digoxin; Enzyme Inhibitors; GABA Modulators; Gonadal Steroid Hormones; Humans; LLC-PK1 Cells; Midazolam; Mixed Function Oxygenases; Nifedipine; Phthalazines; Swine; Testosterone | 2001 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
Topics: Animals; Biometry; Dogs; Drug Evaluation, Preclinical; Haloperidol; Haplorhini; Humans; Injections, Intravenous; Liver; Liver Circulation; Metabolic Clearance Rate; Mifepristone; Molecular Structure; Molecular Weight; Rats; Reproducibility of Results | 2006 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Topics: Animals; Antifungal Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Molecular Dynamics Simulation; Molecular Structure; Structure-Activity Relationship | 2014 |
Relevance of Half-Life in Drug Design.
Topics: Biological Availability; Delayed-Action Preparations; Drug Design; Half-Life; Humans; Pharmaceutical Preparations; Tissue Distribution | 2018 |
[Prinzmetal's angina initiated by interruption of exercise. 5 cases with normal coronary radiograms].
Topics: Adult; Amiodarone; Angina Pectoris; Angina Pectoris, Variant; Atropine; Coronary Angiography; Coronary Disease; Exercise Test; Humans; Male; Middle Aged; Nifedipine | 1979 |
[Prolongation of the effective refractory period on isolated guinea pig atria by some anti-arrhythmia agents: relevance in a comparison of their potentialities].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Function; Dose-Response Relationship, Drug; Guinea Pigs; Heart Atria; Lidocaine; Myocardial Contraction; Nifedipine; Verapamil | 1979 |
Mitochondrial Ca2+ antagonist binding sites are associated with an inner mitochondrial membrane anion channel.
Topics: Amiodarone; Animals; Binding Sites; Calcium Channel Blockers; Calcium Channels; Female; Guinea Pigs; Ion Channels; Male; Mitochondria; Nifedipine; Nitrates; Nitrendipine; Receptors, Nicotinic | 1990 |
Amiodarone, nifedipine, sodium cromoglycate.
Topics: Amiodarone; Cromolyn Sodium; Heart Diseases; Humans; Nifedipine; Plants, Medicinal | 1991 |
Use of drugs in cardiac rehabilitation.
Topics: Adrenergic beta-Antagonists; Amiodarone; Diltiazem; Drug Therapy, Combination; Electrocardiography; Exercise Test; Heart Diseases; Humans; Middle Aged; Nifedipine; Nitrates; Nitroglycerin; Physical Exertion; Verapamil | 1986 |
An experimental approach to the choice of antiarrhythmic therapy.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cats; Coronary Disease; Diltiazem; Lidocaine; Mexiletine; Nifedipine; Phenoxybenzamine; Prazosin; Propafenone; Propiophenones; Propranolol; Stellate Ganglion; Verapamil | 1986 |
[Characteristics of patients with ischemic heart disease under dispensary observation in a regional polyclinic and the evaluation of anti-angina therapy conducted under dispensary conditions].
Topics: Adult; Ambulatory Care; Amiodarone; Angina Pectoris; Coronary Disease; Drug Therapy, Combination; Follow-Up Studies; Humans; Isosorbide Dinitrate; Male; Nifedipine; Nitroglycerin; Propranolol; Time Factors; Vasodilator Agents; Verapamil | 1985 |
Interaction between digoxin and commonly coadministered drugs in children.
Topics: Amiodarone; Child, Preschool; Digoxin; Drug Interactions; Drug Therapy, Combination; Humans; Infant; Infant, Newborn; Nifedipine; Quinidine; Spironolactone; Verapamil | 1985 |
Prognostic significance of electrocardiographic findings in angina at rest. Therapeutic implications.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angina Pectoris; Coronary Angiography; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Nifedipine; Prognosis | 1981 |
[Prinzmetal's angina. Clinical and therapeutic study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angina Pectoris, Variant; Coronary Vasospasm; Drug Evaluation; Humans; Isosorbide Dinitrate; Male; Middle Aged; Nifedipine; Pyridines | 1982 |
[Strategy of the treatment of vasospastic angina pectoris].
Topics: Adult; Amiodarone; Angina Pectoris, Variant; Arteriosclerosis; Coronary Artery Bypass; Coronary Vasospasm; Diltiazem; Humans; Middle Aged; Nifedipine; Nitroglycerin; Radiography; Verapamil | 1983 |
The hyperventilation test as a method for developing successful therapy in Prinzmetal's angina.
Topics: Adult; Amiodarone; Angina Pectoris, Variant; Coronary Vasospasm; Diagnosis, Differential; Electrocardiography; Female; Follow-Up Studies; Humans; Hyperventilation; Isosorbide Dinitrate; Male; Middle Aged; Nifedipine; Phentolamine; Propranolol; Verapamil | 1982 |
[Therapeutic aspects of a case of Prinzmetal's angina].
Topics: Aged; Amiodarone; Angina Pectoris; Angina Pectoris, Variant; Drug Therapy, Combination; Electrocardiography; Humans; Male; Nifedipine; Nitrates; Pindolol; Tetrahydropapaveroline | 1980 |
Dihydropyridine-like effects of amiodarone and desethylamiodarone on thyrotropin secretion and intracellular calcium concentration in rat pituitary.
Topics: Amiodarone; Animals; Calcium; Calcium Channel Blockers; Cells, Cultured; Dihydropyridines; Drug Synergism; Male; Nifedipine; Peptide Fragments; Pituitary Gland; Protein Precursors; Rats; Rats, Wistar; Thyrotropin; Thyrotropin-Releasing Hormone; Triiodothyronine | 1995 |
[The preoperative drug correction of disorders in myocardial functional reserve in patients with ischemic heart disease].
Topics: Adult; Amiodarone; Combined Modality Therapy; Coronary Artery Bypass; Drug Therapy, Combination; Heart; Hemodynamics; Humans; Middle Aged; Myocardial Ischemia; Nifedipine; Preoperative Care; Verapamil | 1994 |
Inhibition of L-type Ca2+ channel current in Xenopus oocytes by amiodarone.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Calcium Channels, L-Type; Female; In Vitro Techniques; Kinetics; Membrane Potentials; Nifedipine; Oocytes; Patch-Clamp Techniques; Rabbits; Recombinant Proteins; RNA, Complementary; Xenopus | 2001 |
Potassium channel currents in rat mesenchymal stem cells and their possible roles in cell proliferation.
Topics: Amiodarone; Animals; Cell Cycle; Cell Proliferation; Cell Survival; Cells, Cultured; Male; Membrane Potentials; Mesenchymal Stem Cells; Nifedipine; Potassium Channel Blockers; Potassium Channels; Protein Subunits; Rats; Rats, Wistar; RNA, Messenger; Verapamil | 2008 |
D-amphetamine toxicity in freshly isolated rat hepatocytes: a possible role of CYP3A.
Topics: Amiodarone; Animals; Central Nervous System Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dextroamphetamine; Enzyme Inhibitors; Hepatocytes; Male; Nifedipine; Rats; Rats, Wistar | 2009 |
Systemic lupus erythematosus associated with vasculitic syndrome (Takayasu's arteritis).
Topics: Adult; Amiodarone; Female; Humans; Lupus Erythematosus, Systemic; Nifedipine; Prednisone; Takayasu Arteritis; Treatment Outcome | 2010 |
Inhibition of ATP-sensitive K+ channels and L-type Ca2+ channels by amiodarone elicits contradictory effect on insulin secretion in MIN6 cells.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Glyburide; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; KATP Channels; Membrane Potentials; Mice; Nifedipine; Osmolar Concentration; Patch-Clamp Techniques; Potassium Channel Blockers; Quinidine | 2011 |